Codexis Stock News

Codexis is a protein engineering company based in the United States that markets its products globally. The protein engineering industry is experiencing rapid growth as increased investment signals gr

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 42 nd Annual Health Care Conference, being held virtually March 7-9, 2022.

Codexis, Inc. (CDXS) CEO John Nicols on Q4 2021 Results - Earnings Call Transcript

Codexis press release (CDXS): Q4 GAAP EPS of -$0.16 beats by $0.04.Revenue of $24.5M (+16.7% Y/Y) beats by $1.35M.Outlook: Company Guides to 2022 Total Revenues of…

Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Codexis (NASDAQ:CDXS) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.20 (-233.3% Y/Y) and the…

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its fourth quarter and fiscal year 2021 financial results on Thursday, February 24, 2022, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Companys financial results and provide a business update.

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation (ODD) for CDX-6512 for the treatment of homocystinuria. CDX-6512 is a gastrointestinal-stable methionine-gamma-lyase, as a potential orally-administered enzyme therapy for homocystinuria (HCU). The FDA also granted the company rare pediatric disease (RPD) designation for CDX-6512. CDX-6512 is currently in pre-IND development and is the most advanced wholly owned program in the Company''s biotherapeutics pipeline. "The orphan drug and rare pediatric disease designations for CDX-6512 further build upon the momentum our engineered enzymes have generated as potential first-in-class oral therapeutics for inborn errors of metabolism," said John Nicols, President and CEO of Codexis. "These designations represent an important step forward in the development of CDX-6512 as a potential treatment of homocystinuria and we look forward to continuing its advancement toward the clinic." CDX-6512 is a gastrointestinal-stable enzyme specifically engineered to be highly resistant to both the acidic conditions of the stomach and to proteases of the upper intestines, enabling it to effectively degrade methionine that is liberated from protein digestion.

In this article we will take a look at whether hedge funds think Codexis, Inc. (NASDAQ:CDXS) is a good investment right now.

Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

David V. Smith to join Board of Directors Elizabeth Smith and Richard Lopez, M.D., to join Scientific Advisory Board ALAMEDA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Acepodia , a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board. "Following our recent Series C funding milestone, we are pleased to bring on a strong roster of industry leaders who bring deep expertise across allogeneic cell therapy development, regulatory affairs, and finance, to help us bring forth next-generation cell therapies for the people who need them most," said Sonny Hsiao, Ph.D., chief executive officer, president and co-founder of Acepodia. David V. Smith Mr. Smith currently serves as a member of the Board of Directors at Codexis and Neurelis and most recently served as Executive Vice President and Chief Financial Officer of Five Prime Therapeutics, acquired by Amgen in 2021.

Two sample Breakout Stocks for Week 52 with better than 10% short-term upside potential and a Dow stock pick. This past week, two stocks beat 10% peak gains in FLGT +19.1% and DYAI +13.8% with Momentu